The aim of this study was to investigate the effect of the
nitric oxide donor isosorbide-5-mononitrate (5-ISMN) alone or in combination with the natural hepatoprotectant with
anti-oxidant activity
silymarin on the
carbon tetrachloride (CCl(4))-induced hepatic injury in rats.
5-ISMN (1.8, 3.6 or 7.2 mg/kg),
silymarin (25 mg/kg) or
5-ISMN (1.8, 3.6 or 7.2 mg/kg) combined with
silymarin was given once daily orally simultaneously with CCl(4) and for 15 days thereafter. Liver damage was assessed by determining serum
enzyme activities and hepatic histopathology.
5-ISMN given at the above doses conferred significant protection against the hepatotoxic actions of CCl(4) in rats, reducing serum
alanine aminotransferase (ALT) levels by 31.2, 39.3 and 61.6%, respectively, when compared with controls. Serum
aspartate aminotransferase (AST) levels decreased by 19.8, 22.7 and 59.4%, respectively, while
alkaline phosphatase (ALP) decreased by 26.1 and 32.6% by the
drug at 3.6 and 7.2 mg/kg, respectively. When
silymarin was added to
5-ISMN (1.8, 3.6 or 7.2 mg/kg), ALT decreased by 32.8, 59.6, 70.2% and AST by 28.7, 50.3, 60%, when compared with CCl(4) control group levels.
Silymarin in combination with 3.6 or 7.2 mg/kg
5-ISMN resulted in 37.5 and 39.2% reductions in ALP when compared with CCl(4) control group. Meanwhile,
silymarin alone reduced ALT, AST and ALP levels by 65.9, 52 and 62.3%, respectively. Blood levels of
reduced glutathione were markedly decreased in CCl(4)-treated rats.
Reduced glutathione levels were increased by the administration of
5-ISMN and restored to near normal values by
silymarin treatment. Histopathological alterations by CCl(4) were markedly reduced
after treatment with
5-ISMN alone or in combination with
silymarin. Histopathologic examination of the livers of CCl(4)-treated rats administered
5-ISMN at 7.2 mg/kg showed marked restoration of the normal architecture of the liver tissue and minimal
fibrosis.
Silymarin co-administered with
5-ISMN resulted in further improvement of the histologic picture. These results indicates that treatment with
5-ISMN protects against hepatocellular
necrosis induced by CCl(4). The study suggests a potential
therapeutic use for
5-ISMN in combination with
silymarin in liver injury.